Monitoring, follow-up and high-risk medicines

• Explain why prescribing is a continuing clinical responsibility rather than a single transaction.
• Design proportionate monitoring and follow-up around the medicine, patient and clinical context.
• Recognise high-risk situations in which missed monitoring can cause serious harm.
• Respond safely to abnormal results, non-attendance, changing physiology and fragmented care.
• Use systems, delegation and multidisciplinary working without losing professional accountability.

A prescription is only one step in a treatment pathway. Safe prescribing includes deciding how benefit and harm will be assessed, who will review the patient, what information must be available, and what will happen if monitoring is missed or abnormal. GMC guidance requires suitable arrangements for monitoring, follow-up and review whether a medicine is prescribed once or repeatedly. This is especially important in frailty, multimorbidity, renal or hepatic impairment, medicines with serious adverse effects, controlled medicines and treatments for which authoritative guidance recommends regular tests.

Monitoring should be linked to the specific risk being managed. A useful plan states what is being monitored, why it matters, when it should be checked, who is responsible for arranging and acting on it, what result or clinical change should trigger action, and how the patient will know what to do if symptoms occur between reviews. The aim is not to order tests mechanically. Monitoring should answer a clinical question and be reviewed when the patient, medicine or treatment goal changes.

A medicine may become high risk because of a narrow therapeutic margin, serious toxicity, interaction potential, dependence risk, complex administration, required laboratory surveillance or the vulnerability of the person taking it. Risk also increases when responsibility is split between teams, records are incomplete, results are not visible across organisations, or a repeat prescription can continue despite overdue review. Electronic alerts can help, but alerts do not replace clinical judgement and can fail through poor configuration or alert fatigue.

A monitoring system is unsafe if it generates results without a clear route for review and action. The person or team ordering or relying on monitoring should know how results will be received, interpreted and acted upon. If a result is unexpected, first confirm its significance in context: the trend, timing, concurrent illness, hydration, recent medicine changes and potential laboratory error may all matter. Urgent abnormalities require timely clinical action rather than simply documenting that the result was seen.

Missed monitoring should not automatically lead either to indefinite continuation or abrupt cessation. The response should be proportionate to the risk of untreated disease, the risk of continued treatment without monitoring, the likely reason for non-attendance and the patient’s circumstances. Attempts to contact the person, alternative arrangements, short supplies or senior/pharmacy advice may be appropriate depending on the medicine and setting. Decisions and safety-netting should be documented.

Monitoring frequently fails at interfaces. A discharge letter that says “GP to monitor” is not enough if the interval, test, target, responsibility and action thresholds are unclear. Shared-care arrangements should make roles explicit and should be accepted rather than assumed. If a clinician receives evidence that monitoring has not occurred, they should not simply rely on the existence of a protocol; the current clinical risk must be assessed and escalated where necessary.

Patient involvement

Patients can strengthen monitoring systems when they understand what the medicine is intended to do, what checks are needed, what symptoms should prompt urgent help and who to contact. This is particularly valuable when treatment crosses care settings. Communication should avoid creating the impression that responsibility has been transferred to the patient: professional systems still need to be reliable.

Practical reasoning framework

For any medicine ask: What benefit am I expecting? What important harm could occur? What clinical or laboratory signal would reveal that harm? When must it be checked? Who owns the result? What action follows an abnormal result? What happens if the check is missed? Can the patient recognise an important warning symptom? This framework is safer than memorising a generic list of “high-risk medicines” because it adapts to the individual patient and local system.

Sources for this module

• GMC - Good practice in proposing, prescribing, providing and managing medicines and devices: Reviewing medicines.
• NICE NG5 - Medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes.
• AWTTC - National Prescribing Indicators 2025-2028 and 2026-2027 specifications.
• Current BNF, product information and local monitoring protocols for medicine-specific requirements.

Educational note: medicine-specific doses, thresholds, contraindications and rapidly changing regulatory requirements must be checked against current authoritative guidance and local policy at the point of care.